Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 4.0 |
Min SIP Amount | ₹1000 | ₹100 |
Expense Ratio | 1.99 | 2.2 |
NAV | ₹19.45 | ₹98.38 |
Fund Started | 10 Nov 2021 | 25 Mar 1997 |
Fund Size | ₹1900.89 Cr | ₹1072.74 Cr |
Exit Load | Exit load of 1%, if redeemed within 15 days. | Exit load of 1%, if redeemed within 30 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 19.51% | 18.64% |
3 Year | 22.94% | 23.05% |
5 Year | - | 23.70% |
1 Year
3 Year
5 Year
Equity | 98.21% | 99.31% |
Cash | -0.95% | 0.69% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Reliance Industries Ltd. | 9.31% |
ITC Ltd. | 9.22% |
Life Insurance Corporation of India | 8.78% |
JIO Financial Services Ltd. | 7.55% |
Piramal Enterprises Ltd. | 5.92% |
Larsen & Toubro Ltd. | 5.77% |
State Bank of India | 4.76% |
Tata Power Company Ltd. | 4.59% |
Birlasoft Ltd. | 4.29% |
Himadri Speciality Chemical Ltd. | 3.14% |
Name | Assets |
---|---|
HDFC Bank Ltd. | 7.21% |
Infosys Ltd. | 4.57% |
ICICI Bank Ltd. | 4.12% |
Dr. Reddy's Laboratories Ltd. | 3.14% |
State Bank of India | 2.74% |
NTPC Ltd. | 2.64% |
REC Ltd. | 2.49% |
Tech Mahindra Ltd. | 2.23% |
Amber Enterprises India Ltd. | 2.16% |
Suven Pharmaceuticals Ltd. | 2.07% |
Name | Ankit A Pande | Satish Ramanathan |
Start Date | 22 Aug 2023 | 01 Oct 2024 |
Name
Start Date
Description | The scheme seeks to achieve capital appreciation in the long-term by primarily investing in a welldiversified portfolio of value stocks. The AMC will have the discretion to completely or partially invest in any of the type of securities stated above with a view to maximize the returns or on defensive considerations. | The scheme aims to provide long term capital growth by investing primarily in a well-diversified portfolio of undervalued securities. |
Launch Date | 10 Nov 2021 | 25 Mar 1997 |
Description
Launch Date